Lexicon Pharmaceuticals, Inc.

2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a brief question and answer session. As a reminder, this call is being recorded today, May 2, 2024. I'll now turn the call over to Lisa DeFranchesco, Head of Investor Relations and Strategy for Lexicon. Please go ahead, Lisa.

Thank you, Jamie. Good afternoon, and welcome to the Lexicon Pharmaceuticals First Quarter 2024 Financial Results Conference Call. Joining me today are Lynelle Coates, Lexicon's Chief Executive Officer and Director, Jeff Wade, Lexicon's President and Chief Financial Officer, Dr. Craig Granowitz, Lexicon's Senior Vice President and Chief Medical Officer, and Tom Garner, Lexicon's Senior Vice President and Chief Commercial Officer. Earlier this afternoon, Lexicon issued a press release announcing financial results for the first quarter of 2024, which is available on our website at www.lexpharma.com and through our SEC filing. A webcast of this call, along with the slide presentation, is available on our website. During this call, we will review the information provided in the release, provide a corporate update, and then use the remainder of our time to answer your questions. Before we begin, let me remind you that we will be making forward-looking statements, including statements related to the safety, efficacy, clinical development, regulatory status, and therapeutic and commercial potential of Impefa, Sotagliflozin, Zynquista, LX9211, LX9851, and our other drug programs. These statements may also include characterizations and projections relating to our commercial launch of Impefa and heart failure, as well as the clinical development, regulatory status, and market opportunity for all of our drug programs. This call may also contain forward-looking statements relating to our growth and future operating results, discovery and development of our drug candidates, strategic alliances, and intellectual property, as well as other matters that are not historical facts or information. Various risks may cause our actual results to differ materially from those expressed or implied in such forward-looking statements. These risks include uncertainties related to our commercial launch of MPEFA, our discussions with the FDA, and other regulatory authorities regarding our drug programs the timing and results of clinical trials, and pre-clinical studies of our drug candidates, our dependence on strategic alliances and other third-party relationships, our ability to obtain patent protection for our discoveries, limitations imposed by patents owned or controlled by third parties, and the requirement of substantial funding to conduct our planned research, development, and commercialization activities. I would now like to turn the call over to Lynelle Coates. Lynelle?

Thank you, Lisa. Good afternoon, everyone, and thank you for joining us on the call. Now before I begin our discussion on Lexicon's results for the first quarter of 2024, I want to acknowledge the press release that went out earlier this week announcing my retirement from Lexicon, which will be effective on my upcoming 10th anniversary with the company on July 7th. I am truly blessed to have had the opportunity to spend the last decade leading this remarkable company. I've had the privilege to work with an outstanding board that contains to support the company and the many amazing and talented employees who are dedicated to Lexicon's mission. It was important to me as I made the decision to embark on the next phase of my personal journey that I lead this company in the strongest possible position. I'm happy to say Lexicon has never been stronger than it is today. As we outlined at our recent investor day, Lexicon has a significant portfolio and pipeline of exciting opportunities. We have a remarkably strong leadership team with the capital to execute on these opportunities to create value for stakeholders. With that, I'd like to turn this call over to our president and CFO, Jeff Wade, to begin our discussions of the results.